Review Identifies 140 Controlled Clinical Trials Related to Cannabis

  • by Paul Armentano, NORML Deputy Director June 4, 2017

    Marijuana researchScientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.

    A pair of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focused on the use of cannabis or cannabinoids in the treatment of chronic or neuropathic pain. Authors identified 35 controlled studies, involving 2,046 subjects, assessing the use of marijuana or cannabinoids in pain management. In January, the National Academy of Sciences acknowledged that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain.

    Cannabinoids have also been well studied as anti-emetic agents and as appetite stimulants. Researchers identified 43 trials evaluating marijuana or its components for these purposes, involving total 2,498 patients. They also identified an additional 14 trials examining the role of cannabis or cannabis-derived extracts in the treatment of multiple sclerosis.

    Researchers also identified several additional trials evaluating the use of cannabis or cannabinoids for Crohn’s disease, Tourette’s syndrome, Parkinson’s disease, glaucoma, epilepsy, and various other indications.

    A 2014 study published in the Journal of the American Medical Association reported that new drugs typically gain FDA approval on the basis of one or two pivotal clinical trials.

    Full text of the study, “Medicinal uses of marijuana and cannabinoids,” appears online here.

    38 responses to “Review Identifies 140 Controlled Clinical Trials Related to Cannabis”

    1. Matt says:

      oh, and to my post for Director Henderson, and I know it is long, but I hope it posts, I should have assauged her concerns or those of others on the council by suggesting tight reguations and controlled grow areas for medical cannabis…sigh…but it is what it is. Okay, last post on this article, I promise, NORML, lol, other than replying to anyone who replies.

    2. Julian says:

      There it is: Democratic Senator Ron Wyden asks what involvement Attorney General Sessions had in the FBI investigation for Russian intereference in our elections, or why he was being investigated:

      Comey: “Due to a variety of reasons… due to reasons that I cannot discuss in an open setting…”

      (Subpeonaaaaa… Waaaait for iiiit…)

      Wyden: “Mychael Flynn was fired four days after Senator Sessions was sworn in. Any relation to that?”

      Comey: “I- I don’t know. Perhaps there was?”

      Here’s the bottom line… At this point its going to be very difficult for the President to fire special prosecutor Mueller, as the Deputy Attorney General Rosenstein must be ordered by the President to do so and Rosenstein, who appointed Mueller, is being investigated by Mueller.

      That means todays testimony will result in subpeonas. That means Sessions’ Drug War has been stalled at very least to allow pivitol legalization in California to take effect and allow for revenue which can be used to declare damages in court. Most importantly, Vermont, Rhode Island and Connecticut are competing to bring the first legislatively enacted marijuana legalization, and the President and his administration are going to be so wrapped up with this investigation that new Federal judges wont be appointed in time to stop marijuana legalization by Federal injunction using the Supremacy Clause.

      Democratic Senator Dick Durbin is grilling Comey on Sessions now too.

      Well Bless your heart Beauregard, goes to show you can run in Alabama but you sho caint hide!

      The fake just got REAL!

    3. Julian says:

      Sessions to testify before the Senate Intelligence Committee:


    Leave a Reply

    Your email address will not be published.